USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 27, 2025.
Key Financial Results
Third Quarter 2025 vs. Third Quarter 2024
Net sales of $214 million versus $200 million, representing 7% year-over-year growth.
Net loss of -$6.5 million versus net earnings of $10.6 million.
Diluted EPS of -$0.36 as compared with $0.56.
Adjusted diluted EPS(1) of -$0.15 as compared with $0.56.
Adjusted EBITDA(2) of $13.8 million versus $24.6 million.
Direct selling Active Customers of 388,000 versus 452,000.
Hiya Active Monthly Subscribers of 193,400.
Q3 2025 Financial Performance
Consolidated Results
Year-Over-Year
Sequentially
Net Sales
$214 million
+7% (No meaningful FX impact)
-9%
Net (Loss) Earnings*
-$6.5 million
N/A
N/A
Diluted EPS
-$0.36
N/A
N/A
Adjusted Diluted EPS(1)
-$0.15
N/A
N/A
Adjusted EBITDA(2)
$13.8 million
-44%
-55%
*Pretax earnings for Q3 2025 totaled $1.8 million with income tax expense of $8.5 million. The adjustment to income taxes during the period, as a result of updating the annual effective tax rate, is about $7.6 million greater than what would have been expected using the previously guided 45% tax rate.
Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.
“USANA provided third quarter results in line with the preliminary results we announced on October 9, 2025,”
said Jim Brown, USANA’s President and Chief Executive Officer.
“We rolled out our enhanced Brand Partner compensation plan